Title:Novel Patents Targeting Interleukin-17A; Implications in Cancer and Inflammation
Volume: 13
Issue: 2
Author(s): Juan F. Santibanez*Suncica Bjelica
Affiliation:
- Group for Molecular Oncology, Institute for Medical Research, University of Belgrade, Dr. Subotica 4, 11129 Belgrade,Serbia
Keywords:
Cancer, inflammation, interleukin-17A (IL-17A), interleukin-17 Receptor A (IL-17RA), patents, signaling, therapies.
Abstract: Background: IL-17A is a founding member of the IL-17 family that has been implicated in
the pathogenesis of inflammatory-associated diseases such as cancer and autoimmune disease. In cancer,
IL-17A participates in many key events for tumor development, in part by affecting innate and
adaptive immune system and also by direct modulation of many pro-tumor events. Moreover, IL-17A
dysregulation at the site of inflammation is associated with rheumatoid arthritis, multiple sclerosis,
psoriasis, among others. IL-17A has emerged as a topic of interest and is under profound investigation
for its involvement in several types of inflammatory-associated diseases.
Objective: This review aims to present an overview of the state of the art of IL-17A role in cancer and
inflammation, as well as to describe recent patents targeting IL-17A with relevant clinical and biological
properties for the prevention and treatment of cancer and inflammatory diseases.
Methods: Relevant information was obtained by searching in PubMed using IL-17A or IL-17, cancer
and inflammation as keywords, while relevant patents were obtained mainly from Google Patents.
Results: Literature data indicated IL-17A as important biomolecule in the physiopathology of cancer
and inflammatory diseases. Whereas, novel patents (2010 to 2017) targeting IL-17A are focused mainly
on describing strategies to modulate IL-17A per se, co-modulation by bispecific antibodies to blocking
IL-17A and important cytokines for IL-17A functions, upstream mechanisms and compounds to regulate
IL-17A expression.
Conclusion: The promising effects of patented agents against IL-17A may open new opportunities to
therapeutic intervention targeting at different levels of involvement in the pathogenesis of cancer and
inflammatory diseases.
